Investor's Business Daily on MSN37m
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter DrugNeurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback